StockData

Enovis vs Inogen

ENOV and INGN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENOV and INGN compare

Enovis is the larger company, worth 11 times as much as Inogen ($1.6B against $151M).

Inogen grew revenue faster over the last twelve months (13.7% versus 3.3% for Enovis).

Inogen keeps more of each dollar of sales as profit, with a net margin of −9.3% compared with −22.9% at Enovis.

Inogen scores higher on the StockData Score (12 against 7 for Enovis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENOVINGN
Size and price
Market cap$1.6B$151M
Share price$27.68$5.69
Change, 1 year−11.4%−19.7%
Change, 5 years−81.7%−82.8%
Beta (5Y)1.141.25
Employees7,802314
StockData Score
Total score712 (better)
Valuation score23 (better)
Growth score2 (better)1
Performance score13 (better)
Health score25 (better)
Dividend score00
Valuation
P/S0.7×0.4× (better)
P/B1.1×1.0× (better)
EV/EBITDA3.3×–
P/FCF22.9×–
FCF yield4.4% (better)−7.5%
Fair value–$17.93
Margin of safety–68.3%
Growth
Revenue growth (TTM)3.3%13.7% (better)
Revenue growth, 5Y average14.9% (better)2.5%
Profitability
Gross margin61.3% (better)44.1%
Operating margin−20.6%−11.0% (better)
Net margin−22.9%−9.3% (better)
FCF margin3.0% (better)−3.0%
Return on equity−30.0%−20.0% (better)
Return on invested capital−12.3% (better)−49.2%
Financial health
Debt / equity0.84 (better)0.00
Net debt / EBITDA1.43–
Interest coverage−14.7×–
Current ratio2.152.96 (better)
Altman Z-score0.291.30 (better)
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions122%72.9%
Held by insiders2.7%3.7%
Insider net buying, 12 months$792K (better)−$143K
Superinvestors holding1–
Short interest, % of float18.8%5.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.